ORFO
Orforglipron
Not a peptide. A non-peptide small molecule and a partial agonist at the GLP-1 receptor, binding it at a site distinct from where the peptide agonists bind. Being a small molecule rather than a peptide is the structural reason it survives the gut, where the peptide GLP-1 analogues do not.
Orforglipron has 33 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 29,343 planned or enrolled participants across the 33 studies that published a figure. An FDA-approved product contains Orforglipron — FOUNDAYO (NDA220934). 117 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Orforglipron; the registry search is fuzzy, so every match is re-checked. None of this says whether Orforglipron works or is safe.
FDA status
Approved
Human studies
33
Furthest phase
Phase 4
Papers, 10 yr
117
Readership
9,289
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
33
Registered human studies
Phase 4
Furthest phase reached
29,343
Planned or enrolled participants, across 33 studies that published a figure
Approved
FDA-approved product — FOUNDAYO
50 loose registry matches were checked and 33 confirmed — 17 named something else and were discarded. We count a study only when Orforglipron is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Orforglipron is, and what it has been studied for
Orforglipron is classified by ChEMBL as a small molecule, and appears in trial registrations under LY-3502970 and LY3502970. Its FDA substance identifier is 7ZW40D021M.
Across 33 registered trials, it has been studied in Obesity, Overweight, Type 2 Diabetes and Healthy. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Eli Lilly and Company and Massachusetts General Hospital. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Orforglipron reached Phase 4 across 33 registered trials.
An FDA-approved product contains Orforglipron. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Orforglipron?
Papers published each year that name Orforglipron in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 14 | 8 | Yes |
| 2024 | 17 | 10 | Yes |
| 2025 | 33 | 11 | Yes |
| 2026 | 60 | 4 | No |
117 papers and 33 registered trials between 2017 and 2026. A paper counts when “Orforglipron” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Orforglipron
117 indexed papers name Orforglipron in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
Collected 2026-08-02from PubMed, phrase-matched on “Orforglipron” in title and abstract. Run the same search.
About Orforglipron
Not a peptide. A non-peptide small molecule and a partial agonist at the GLP-1 receptor, binding it at a site distinct from where the peptide agonists bind. Being a small molecule rather than a peptide is the structural reason it survives the gut, where the peptide GLP-1 analogues do not.
- Also known as
- LY3502970 · OWL833
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.